AI guidance system for robotic rectal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a machine-learning (AI) system that may help guide surgeons during robotic rectal cancer operations. It’s meant to support safer, more accurate surgery while comparing outcomes to standard surgical guidance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer and your surgery is planned as robot-assisted rectal removal
- Your pre-surgery urinary and rectal function is intact (not significantly impaired)
- You can fully understand the study and give informed consent
- You have not had other cancers within the last 5 years before your rectal cancer diagnosis
- You have not had abdominal surgery before, except specific minor cases (appendix removal, gallbladder removal, or C-section)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses special imaging to guide surgery for rectal cancer. It studies whether detailed scans taken before surgery can help doctors remove the cancer more precisely.
This trial tests an artificial-intelligence support tool that helps surgeons make decisions during surgery for rectal cancer. If you qualify, the tool may be used alongside the surgical team to support safer, more effective care.
This trial is testing a computer model that helps doctors predict how difficult rectal cancer surgery will be, so they can choose the best approach. The study aims to improve surgical planning and outcomes for patients.
This study tests an AI system that helps identify cancer or polyp findings during rectal surgery or assessment, using real-time information. It may help surgeons classify tissue more accurately while you are already getting treatment.
This trial tests an AI-based platform to help plan the best surgery for people with colon or rectal cancer. It aims to improve decision-making by both doctors and patients.
This study is testing whether an artificial intelligence system can find very small amounts of leftover cancer (minimal residual disease) after treatment for rectal or esophageal cancer. If successful, this could help doctors detect a relapse earlier than current methods.
Hear when a new Rectum Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.